FUMITAKA SHIMIZU, Nakamori M. Blood-Brain Barrier Disruption in Neuroimmunological Disease. International journal of molecular sciences. 2024
Hicks SM, Frias JA, Mishra SK, Scotti M, Muscato DR, Valero MC, Adams LM, Cleary JD, Nakamori M, Wang E, et al. Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1. Molecular therapy. Nucleic acids. 2024
Kenya Kubo, Yoshinori Oie, Ryota Koto, Nozomi Nishida, Chifune Kai, Sayo Maeno, Tomoya Kubota, Masayuki Nakamori, Masanori P Takahashi, Motokazu Tsujikawa, et al. Analysis of Corneal Phenotypes in Japanese Patients With Myotonic Dystrophy Type 1. Cornea. 2024
Naoki Suzuki, Madoka Mori-Yoshimura, Masahisa Katsuno, Masanori P Takahashi, Satoshi Yamashita, Yasushi Oya, Atsushi Hashizume, Shinichiro Yamada, Masayuki Nakamori, Rumiko Izumi, et al. Safety and efficacy of aceneuramic acid in GNE myopathy: open-label extension study. Journal of neurology, neurosurgery, and psychiatry. 2024
Sayo Maeno, Oie Y, Koto R, Nishida N, Yamashita A, Yoshioka M, Kai C, Soma T, Koh S, Masahito Yoshihara, et al. Comparison of Scheimpflug and Anterior Segment Optical Coherence Tomography Imaging Parameters for Japanese Patients With Fuchs Endothelial Corneal Dystrophy With and Without TCF4 Repeat Expansions. Cornea. 2024
T. Uehara, C. J. Choong, H. Hayakawa, Y. Kasahara, T. Nagata, T. Yokota, K. Baba, M. Nakamori, S. Obika, H. Mochizuki. Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid Downregulate SNCA Expression and Improve Motor Function in Parkinson's disease Mouse Models. MOVEMENT DISORDERS. 2017. 32